Galapagos increases share capital through warrant exercises
September 21 2017 - 4:00PM
Mechelen,
Belgium; 21 September 2017, 22.00 CET; regulated information -
Galapagos NV (Euronext & NASDAQ: GLPG) announces a share
capital increase arising from warrant exercises.
Galapagos issued 28,100 new
ordinary shares on 21 September 2017, for a total capital
increase (including issuance premium) of €268,478.00.
Pursuant to the warrant exercise
program of Galapagos' executive committee, executive committee
members automatically are committed to exercise a minimum number of
warrants, subject to certain conditions. In accordance with the
rules of this program, CEO Onno van de Stolpe exercised 15,000
warrants and two other executive committee members exercised an
aggregate number of 10,000 warrants.
In accordance with Belgian
transparency legislation[1], Galapagos
notes that its total share capital currently amounts to
€275,287,943.48, the total number of securities conferring voting
rights is 50,895,778, which is also the total number of voting
rights (the "denominator"), and all securities conferring voting
rights and all voting rights are of the same category. The total
number of rights (warrants) to subscribe to not yet issued
securities conferring voting rights is 4,011,807, which equals the
total number of voting rights that may result from the exercise of
these warrants. Galapagos does not have any convertible bonds or
shares without voting rights outstanding.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage
biotechnology company specialized in the discovery and development
of small molecule medicines with novel modes of action. Our
pipeline comprises Phase 3, 2, 1, pre-clinical and discovery
studies in cystic fibrosis, inflammation, fibrosis, osteoarthritis
and other indications. We have discovered and developed filgotinib:
in collaboration with Gilead we aim to bring this JAK1-selective
inhibitor for inflammatory indications to patients all over the
world. Galapagos is focused on the development and
commercialization of novel medicines that will improve people's
lives. The Galapagos group, including fee-for-service subsidiary
Fidelta, has approximately 550 employees, operating from its
Mechelen, Belgium headquarters and facilities in The Netherlands,
France, and Croatia. More information at www.glpg.com.
Contacts
Investors:
Elizabeth Goodwin
VP IR & Corporate Communications
+1 781 460 1784
Paul van der Horst
Director IR & Business Development
+31 71 750 6707
ir@glpg.com
Media:
Evelyn Fox
Director Communications
+31 6 53 591 999
communications@glpg.com
Forward-looking
statements
This release may contain forward-looking
statements. Such forward-looking statements are not guarantees of
future results. These forward-looking statements speak only as of
the date of publication of this document. Galapagos expressly
disclaims any obligation to update any forward-looking statements
in this document, unless specifically required by law or
regulation.
[1]
Belgian Act of 2 May 2007 on the disclosure of
major shareholdings in issuers whose shares are admitted to trading
on a regulated market
Warrant exercises Q3
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Galapagos NV via Globenewswire
Galapagos NV (NASDAQ:GLPG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Galapagos NV (NASDAQ:GLPG)
Historical Stock Chart
From Apr 2023 to Apr 2024